SARS-CoV-2-Infektion und interstitielle Lungenerkrankungen – Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin

Zusammenfassung Die SARS-CoV-2-Pandemie hat in erheblichem Umfang die Diagnostik und Therapie interstitieller Lungenerkrankungen (ILD) beeinflusst. Insbesondere in der Frühphase der Pandemie und unter dem Einfluss der Delta-Variante ist es zu zahlreichen COVID-19-Pneumonien gekommen, in deren Gefolge sich bestehende interstitielle Lungenerkrankungen verschlechtert haben, neue entstanden sind oder entdeckt wurden. Den Einfluss einer SARS-CoV-2-Infektion – mit oder Viruspneumonie – auf vorbestehende ILD sowie die weitere Entwicklung neu entstandener pulmonaler Infiltrate und Konsolidierungen abzuschätzen, zu diagnostizieren und angemessen zu behandeln stellt eine nahezu tägliche Herausforderung in den interdisziplinären ILD-Boards dar. Mit diesem Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungstherapie e.V. (DGP) werden auf Basis des aktuellen Wissensstandes Antworten auf die wichtigsten Fragestellungen gegeben.

[1]  P. Jaksch,et al.  Gamma-glutamyltransferase is a strong predictor of secondary sclerosing cholangitis after lung transplantation for COVID-19 ARDS , 2022, The Journal of Heart and Lung Transplantation.

[2]  Yan V. Sun,et al.  A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality , 2022, American journal of respiratory and critical care medicine.

[3]  Tucker F. Johnson,et al.  Late Complications of COVID-19: A Morphologic, Imaging, and Droplet Digital Polymerase Chain Reaction Study of Lung Tissue. , 2022, Archives of pathology & laboratory medicine.

[4]  G. Foti,et al.  One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study , 2022, Respiratory Research.

[5]  V. Poletti,et al.  Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection , 2022, European Respiratory Journal.

[6]  A. West,et al.  How COVID-19 interacts with interstitial lung disease , 2022, Breathe.

[7]  V. Poletti,et al.  European Respiratory Society statement on long COVID follow-up , 2022, European Respiratory Journal.

[8]  C. Bermudez,et al.  The Case for Prolonged ECMO for COVID-19 ARDS as a Bridge to Recovery or Lung Transplantation , 2022, Transplantation.

[9]  M. Peltz,et al.  ECMO Long Haulers: A Distinct Phenotype of COVID-19–Associated ARDS With Implications for Lung Transplant Candidacy , 2022, Transplantation.

[10]  A. Suzuki,et al.  COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review , 2022, Frontiers in Medicine.

[11]  E. Herzog,et al.  An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination , 2022, Chest.

[12]  A. Bharat,et al.  Clinical Characteristics and Outcomes of Patients With COVID-19-Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant. , 2022, JAMA.

[13]  S. Keshavjee,et al.  Lung Transplantation for Covid-19–Related Respiratory Failure in the United States , 2022, The New England journal of medicine.

[14]  R. Choudhary,et al.  Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series. , 2021, Advances in respiratory medicine.

[15]  J. Bhiman,et al.  Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.

[16]  Lakshmi Narayana Yaddanapudi,et al.  High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) , 2021, European Respiratory Journal.

[17]  G. Raghu,et al.  Interstitial lung disease before and after COVID-19: a double threat? , 2021, European Respiratory Journal.

[18]  B. Saha,et al.  Indications, Clinical Utility, and Safety of Bronchoscopy in COVID-19 , 2021, Respiratory Care.

[19]  A. Niimi,et al.  Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19 , 2021, Internal medicine.

[20]  J. Myers,et al.  Usual Interstitial Pneumonia is the Most Common Finding in Surgical Lung Biopsies from Patients with Persistent Interstitial Lung Disease Following Infection with SARS-CoV-2 , 2021, EClinicalMedicine.

[21]  M. Turan,et al.  Comparison of pirfenidone and corticosteroid treatments at the COVID‐19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography , 2021, International journal of clinical practice.

[22]  K. Rabe,et al.  S1-Leitlinie Post-COVID/Long-COVID , 2021, Pneumologie.

[23]  B. Saez,et al.  Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19 , 2021, Chest.

[24]  P. Tafforeau,et al.  The Bronchial Circulation in COVID-19 Pneumonia , 2021, American journal of respiratory and critical care medicine.

[25]  Lanjuan Li,et al.  One-year follow-up of chest CT findings in patients after SARS-CoV-2 infection , 2021, BMC Medicine.

[26]  J. Park,et al.  COVID-19 vaccine-related interstitial lung disease: a case study , 2021, Thorax.

[27]  E. Renzoni,et al.  Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease , 2021, The Lancet Respiratory Medicine.

[28]  Y. Umemura,et al.  Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study , 2021, International Journal of Infectious Diseases.

[29]  Mark G. Jones,et al.  3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study , 2021, The Lancet Respiratory Medicine.

[30]  E. Hoffman,et al.  Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length , 2021, Thorax.

[31]  J. Sohn,et al.  Interstitial lung disease increases susceptibility to and severity of COVID-19 , 2021, European Respiratory Journal.

[32]  I. Pavord,et al.  Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study , 2021, The Lancet Respiratory Medicine.

[33]  K. Rabe,et al.  Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. , 2021, The Lancet. Respiratory medicine.

[34]  A. Crisanti,et al.  Machine learning‐based analysis of alveolar and vascular injury in SARS‐CoV‐2 acute respiratory failure , 2021, The Journal of pathology.

[35]  P. Venkatesan.  NICE guideline on long COVID , 2021, The Lancet Respiratory Medicine.

[36]  P. Molyneaux,et al.  Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment , 2021, Annals of the American Thoracic Society.

[37]  Guohui Fan,et al.  RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.

[38]  S. Eisenmann,et al.  Empfehlungen zur Durchführung einer Bronchoskopie in Zeiten der COVID-19-Pandemie: Update 12/2020 , 2020, Pneumologie.

[39]  R. Eberhardt,et al.  [Recommendations for Performing Bronchoscopy in Times of the COVID-19 Pandemic - Update 12/2020]. , 2020, Pneumologie.

[40]  F. Kronenberg,et al.  Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial , 2020, European Respiratory Journal.

[41]  V. Cottin,et al.  Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease , 2020, American journal of respiratory and critical care medicine.

[42]  A. Sung,et al.  COVID-19 Test Correlation Between Nasopharyngeal Swab and Bronchoalveolar Lavage in Asymptomatic Patients , 2020, Chest.

[43]  M. Massari,et al.  May 2020: Is It Always COVID-19 No Matter What? , 2020, International medical case reports journal.

[44]  P. Laterre,et al.  Short telomeres increase the risk of severe COVID-19 , 2020, Aging.

[45]  Jordan J. Clark,et al.  Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study , 2020, American journal of respiratory and critical care medicine.

[46]  N. Gebauer,et al.  Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD) , 2020, Frontiers in Immunology.

[47]  H. Shan,et al.  Differential Diagnosis of COVID-19 Pneumonia in Cancer Patients Received Radiotherapy , 2020, International journal of medical sciences.

[48]  S. El-Chemaly,et al.  Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study , 2020, American journal of respiratory and critical care medicine.

[49]  J. Roman,et al.  Acute Exacerbation of Interstitial Lung Disease as a Sequela of COVID-19 Pneumonia , 2020, The American Journal of the Medical Sciences.

[50]  G. Berry,et al.  Radiology-pathology Correlation in Recovered COVID-19, Demonstrating Organizing Pneumonia. , 2020, American journal of respiratory and critical care medicine.

[51]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[52]  M. Trauner,et al.  Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series , 2020, Annals of Internal Medicine.

[53]  Meilin Liu,et al.  Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis , 2020, Journal of Infection.

[54]  H. Sitter,et al.  S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose , 2020, Pneumologie.

[55]  Peixun Zhang,et al.  Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study , 2020, Bone Research.

[56]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[57]  B. Rehbock.  Protokollempfehlungen der AG DRauE zur Durchführung von Low-Dose-Volumen-HRCT-Untersuchungen der Lunge , 2017, RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

[58]  D. Lynch,et al.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.

[59]  J. Joh,et al.  Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea , 2016, Infection & chemotherapy.

[60]  Lixin Xie,et al.  Follow-up Study on Pulmonary Function and Lung Radiographic Changes in Rehabilitating Severe Acute Respiratory Syndrome Patients After Discharge , 2005, Chest.